Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA), which has announced a transition to the name LeonaBio, Inc. with a new ticker "LONA," regularly issues news updates as a clinical-stage biopharmaceutical company headquartered in the Seattle, Washington area. Its press releases focus on the development of novel small molecule therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).
News for ATHA commonly covers progress in the company’s lead programs, lasofoxifene and ATH-1105. Updates include clinical trial milestones such as completion of a first-in-human Phase 1 trial of ATH-1105 in healthy volunteers, presentations of safety, tolerability and pharmacokinetic data, and enrollment status for the Phase 3 ELAINE-3 trial of lasofoxifene in ER+, HER2-negative, ESR1-mutated metastatic breast cancer. The company also reports on preclinical findings for ATH-1105 in ALS models and scientific presentations at major neurology and ALS-focused conferences.
Investors following ATHA news will also see corporate and regulatory developments, including announcements about a 10-for-1 reverse stock split aimed at maintaining Nasdaq listing requirements, notices of regained compliance with the minimum bid price rule, and details of private placement financings intended to support clinical and regulatory milestones. Additional releases describe Athira’s strategic alternatives review and its licensing agreements with Sermonix Pharmaceuticals and Ligand Pharmaceuticals for lasofoxifene.
This news feed provides a centralized view of Athira/LeonaBio’s clinical, scientific and corporate disclosures, allowing readers to track how its oncology and neurology pipelines evolve over time and how financing and licensing arrangements relate to ongoing and planned trials.
Athira Pharma announced positive results from a Phase 1 clinical trial of fosgonimeton (ATH-1017) in Alzheimer’s patients. The trial demonstrated a statistically significant improvement in Event-Related Potential (ERP) P300 latency, indicating potential procognitive properties. Fosgonimeton showed a positive safety and tolerability profile across all dosages. The drug has been named by the World Health Organization, enhancing its recognition. Upcoming data from the Phase 2 ACT-AD trial are expected in Q2 2022, showcasing ongoing commitment to developing treatments in neurology.
Athira Pharma (NASDAQ: ATHA) has appointed Grant Pickering to its Board of Directors. Pickering, who has over 30 years in drug development and commercialization, previously served as CEO at Vaxcyte and other firms. Athira's President, Mark Litton, emphasized Pickering's extensive experience as a valuable asset for advancing therapies targeting neurological diseases, including Alzheimer's. Athira’s lead candidate, ATH-1017, aims to restore neuronal health and combat neurodegeneration. The company is currently in late stages of clinical development for innovative therapies.
Athira Pharma (NASDAQ: ATHA) has initiated patient dosing in the SHAPE Phase 2 clinical trial for ATH-1017, targeting Parkinson's disease dementia and Dementia with Lewy bodies. ATH-1017 aims to enhance Hepatocyte Growth Factor (HGF) activity to address neurodegeneration. The randomized trial will enroll 75 participants in the U.S., assessing cognitive, functional, and behavioral endpoints over 26 weeks. Current therapies for these conditions are limited, highlighting a significant need for innovative treatments.
Athira Pharma (NASDAQ: ATHA) reported progress in its clinical programs and outlook for 2022, highlighting the ACT-AD Phase 2 study with topline data expected in 2Q22. The LIFT-AD Phase 3 study of ATH-1017 in Alzheimer's disease is expanding enrollment from 300 to 420 participants to bolster statistical power for secondary endpoints, aiming for top-line data by 1H23. Additionally, the SHAPE Phase 2 trial for Parkinson's disease dementia was initiated, while an IND application for ATH-1020 has been filed. The company anticipates robust developments across its pipeline, focusing on neurodegenerative diseases.
Athira Pharma (NASDAQ: ATHA) announced its third quarter 2021 financial results, highlighting a cash position of $339.4 million. The company completed enrollment in the ACT-AD trial, with topline data expected in H1 2022, while the LIFT-AD trial is actively recruiting, aimed for completion by 2022. R&D expenses rose to $10.7 million compared to $5.8 million in 2020. The net loss increased to $15.7 million ($0.42 per share) from $8.5 million ($1.12 per share) in the same quarter the previous year.
Athira Pharma (NASDAQ: ATHA) announced progress on its late-stage clinical trials for ATH-1017, aimed at treating mild-to-moderate Alzheimer’s disease, during the CTAD conference in Boston. Both trials, ACT-AD and LIFT-AD, are randomized and placebo-controlled, showing balanced baseline characteristics and encouraging safety profiles. Topline data from the ACT-AD trial is expected in the first half of 2022, providing insights on cognitive function and neurodegeneration. The company emphasizes the potential of ATH-1017 in addressing unmet patient needs in Alzheimer's treatment.
Athira Pharma (NASDAQ: ATHA) announces participation in two investor conferences: the Stifel 2021 Virtual Healthcare Conference on November 15 at 2:40 p.m. ET and the Jefferies 2021 London Healthcare Conference available on-demand from November 18 at 4:00 a.m. ET. Both events will feature a fireside chat format. Live webcasts will be accessible through the Investors section of the Athira website, with archived replays available for 30 days. Athira focuses on developing small molecules to restore neuronal health and combat neurodegeneration, particularly in Alzheimer’s and Parkinson’s.
Athira Pharma (NASDAQ: ATHA) announced an upcoming webinar featuring neurologist Dr. John Michael Olichney. The event is scheduled for Friday, Nov. 5, at 9 a.m. PT / 12 p.m. ET, focusing on the P300 latency measure for assessing cognitive function and its correlation with working memory. Key presentations will also include insights from Kevin Church on ATH-1017, a small molecule therapeutic for Alzheimer’s and Parkinson’s dementia, and Hans Moebius on the ongoing ACT-AD trial. The trial's topline data is expected in early 2022.
Athira Pharma (NASDAQ: ATHA) has completed enrollment for its Phase 2 ACT-AD clinical trial, investigating ATH-1017 for mild-to-moderate Alzheimer’s disease. The trial enrolled 77 patients across the U.S. and Australia to evaluate cognitive improvements over 26 weeks. Topline results are expected in the first half of 2022. CEO Mark Litton emphasized the significance of this milestone, noting the potential for ATH-1017 to offer new treatment options. The company also plans to initiate a clinical trial for Parkinson’s disease dementia later this year.
Athira Pharma announced the appointment of Mark Litton, Ph.D., M.B.A., as the new CEO, succeeding Dr. Leen Kawas, who has resigned amid an investigation into allegations regarding her doctoral research. The special committee found that Dr. Kawas altered images in her past research, but clarified that this did not involve the company’s lead candidate, ATH-1017. This candidate is currently in late-stage development for Alzheimer’s treatment, with promising results from prior trials. The company emphasizes its commitment to integrity and scientific research.